TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22152942

Group type: EXPERIMENTAL
Intervention: Harmonic Focus(®) device
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional surgery (scissors and electrocautery)
Number of subjects: 106
Study: 21311485

Group type: EXPERIMENTAL
Intervention: Akatinol memantine (20 mg/day, 10 mg twice a day) for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17655918

Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16267249

Group type: EXPERIMENTAL
Intervention: Fish oil supplement
Number of subjects: 402

Group type: COMPARATOR
Intervention: Olive oil supplement
Number of subjects: 402
Study: 11955602

Group type: EXPERIMENTAL
Intervention: Immucytal
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 10499716

Group type: EXPERIMENTAL
Intervention: Noncompliance with prescription medications
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Noncompliant patients discharged
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Noncompliant patients admitted
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Yearly medication costs
Number of subjects: 100
Study: 7492102

Group type: EXPERIMENTAL
Intervention: Valaciclovir 1,000 mg three times daily for 7 days
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Valaciclovir 1,000 mg three times daily for 14 days
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 7 days
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Valaciclovir and Acyclovir
Number of subjects: 1141
Study: 1771290

Group type: EXPERIMENTAL
Intervention: Cubital arterial catheterization
Number of subjects: 76

Group type: COMPARATOR
Intervention: Radial arterial catheterization
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 76
Study: 7177293

Group type: EXPERIMENTAL
Intervention: Acetate dialysate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bicarbonate dialysate
Number of subjects: 17
Study: 30640209

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27033879

Group type: EXPERIMENTAL
Intervention: Forest therapy (staying at a recreational forest site)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Urban group (staying in an urban hotel)
Number of subjects: 59
Study: 26343833

Group type: EXPERIMENTAL
Intervention: Sarcosine (2g)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 24817030

Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Number of subjects: 81

Group type: COMPARATOR
Intervention: Venturi mask (control)
Number of subjects: 81
Study: 22995933

Group type: EXPERIMENTAL
Intervention: Early responders (within 2 weeks)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Delayed responders (3-4 weeks)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Early responders and delayed responders
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: PANSS total percent change
Number of subjects: 263
Study: 19443340

Group type: EXPERIMENTAL
Intervention: Pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice
Number of subjects: 0
Study: 18097810

Group type: EXPERIMENTAL
Intervention: Test product (Glubosil, 30 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Reference product (Actos, 30 mg)
Number of subjects: 35
Study: 15102658

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) plus Bevacizumab (Avastin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11581139

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD therapy in patients with ≥2 risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD therapy in patients with <2 risk factors
Number of subjects: 0
Study: 9699906

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (450 mg, twice a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8205291

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of cardiovascular events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of organ damage
Number of subjects: 0
Study: 3709244

Group type: EXPERIMENTAL
Intervention: Killed influenza virus vaccine
Number of subjects: 318
Study: 30300367

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 27927221

Group type: EXPERIMENTAL
Intervention: 400 IU daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 45000 IU weekly for 2 months then 400 IU daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2000 IU daily for 3 months then 1000 IU daily
Number of subjects: 0
Study: 25440793

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (5 mg twice daily)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 23290333

Group type: EXPERIMENTAL
Intervention: 6-month multicomponent cognitive group intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active control group (later intervention)
Number of subjects: 24
Study: 19524275

Group type: EXPERIMENTAL
Intervention: Motor Function Measure (MFM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Face Manual Muscle Testing (Face MMT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MFM dimensions D1, D2, D3
Number of subjects: 100
Study: 18569227

Group type: EXPERIMENTAL
Intervention: Structured asthma diary as part of the educational intervention
Number of subjects: 424
Study: 18635468

Group type: EXPERIMENTAL
Intervention: Clevidipine (0.4‐8.0 microg kg(‐1) min(‐1))
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (20% lipid emulsion)
Number of subjects: 110
Study: 15009069

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 17beta 0.05 mg and norethisterone acetate 0.125 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11860772

Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A vaccine (H2 Strain, 10^7.0 TCID(50)) after booster dose
Number of subjects: 42
Study: 9354540

Group type: EXPERIMENTAL
Intervention: Continuous intravenous furosemide (0.1 mg x kg(‐1) x h(‐1))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intermittent intravenous furosemide (1 mg/kg bolus every 4 hours)
Number of subjects: 26
Study: 8233511

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 3469164

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg or 300 mg b.i.d.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Amoxicillin 1 g b.i.d. or t.i.d.
Number of subjects: 44
Study: 30507559

Group type: COMPARATOR
Intervention: Local anesthetic injection (1 ml lidocaine of 0.5% for each trigger point)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Local anesthetic injection + Sham kinesiotaping
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Local anesthetic injection + kinesiotaping
Number of subjects: 76
Study: 30497995

Group type: EXPERIMENTAL
Intervention: 12 g acute dose of MSM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 g, 3 g, or 6 g daily doses of MSM for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 g daily dose of MSM
Number of subjects: 0
Study: 26856517

Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Combination of Swaddling and Breastfeeding
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 131
Study: 24863152

Group type: EXPERIMENTAL
Intervention: Discontinue statins
Number of subjects: 381

Group type: COMPARATOR
Intervention: Continue on statins
Number of subjects: 381
Study: 21597108

Group type: EXPERIMENTAL
Intervention: Counselling by an occupational physician (OP) addressing workplace barriers and leisure-time physical activity, consisting of two counselling sessions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counselling by an occupational physician (OP) focusing on enhanced physical activity.
Number of subjects: 0
Study: 19571632

Group type: EXPERIMENTAL
Intervention: Aroma essential oil inhalation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Carrier oil inhalation (placebo)
Number of subjects: 36
Study: 17309588

Group type: EXPERIMENTAL
Intervention: Vector ultrasonic system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (S/RP)
Number of subjects: 20
Study: 15230446

Group type: EXPERIMENTAL
Intervention: Owner education (EDU) treatment group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control treatment group
Number of subjects: 60
Study: 11478454

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 100
Study: 9610790

Group type: EXPERIMENTAL
Intervention: Beta-Carotene (30 mg) and Retinyl Palmitate (25,000 units) daily
Number of subjects: 12184

Group type: COMPARATOR
Intervention: Placebo (3-month run-in)
Number of subjects: 12184
Study: 7833223

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg once daily)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 205

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 205
Study: 2979233

Group type: EXPERIMENTAL
Intervention: Ceruletide (2.5 ng kg‐1 min‐1 for 1 hour)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 29425564

Group type: EXPERIMENTAL
Intervention: CR+F (3 months of standard CR with three pedometer-based, face-to-face PA group counseling sessions followed by 9 months of aftercare with three general lifestyle, face-to-face group counseling sessions)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: CR+T (3 months of standard CR followed by 9 months of aftercare with five to six general lifestyle, telephonic counseling sessions)
Number of subjects: 731

Group type: COMPARATOR
Intervention: CR-only (3 months of standard CR)
Number of subjects: 731
Study: 27050908

Group type: EXPERIMENTAL
Intervention: Oral glucosamine sulfate (GlcN-S) from T0 to T3, then combined treatment of mud-bath therapy and GlcN-S from T3 to T6.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combined treatment of mud-bath therapy and GlcN-S from T0 to T3, then GlcN-S alone from T3 to T6.
Number of subjects: 45
Study: 24961378

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI) from 1 of 18 counselors with varying characteristics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving assessment only
Number of subjects: 0
Study: 24351556

Group type: EXPERIMENTAL
Intervention: Rosa roxburghii tratt preparation (120 ml/d for one month)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: SOD-enriched rosa roxburghii tratt juice (120 ml/d for one month)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (healthy residents)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Rosa roxburghii tratt preparation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: SOD-enriched rosa roxburghii tratt juice
Number of subjects: 62
Study: 20672729

Group type: EXPERIMENTAL
Intervention: Helioflow (Ivoclar Vivadent)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tetric Flow
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: experimental flowable composite
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heliomolar HB (Ivoclar Vivadent)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No base
Number of subjects: 30
Study: 19166420

Group type: EXPERIMENTAL
Intervention: lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days (7LFT group)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days (14LFT group)
Number of subjects: 463

Group type: COMPARATOR
Intervention: lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days (7LPZ group)
Number of subjects: 463

Group type: COMPARATOR
Intervention: lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days (14LPZ group)
Number of subjects: 463
Study: 16624682

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Baseline mitral regurgitation
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Plasma brain natriuretic peptide (BNP) levels
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 776
Study: 11978752

Group type: EXPERIMENTAL
Intervention: Infants with CLD
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Infants with RDS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: RDS and CLD groups
Number of subjects: 43
Study: 9925196

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite coated cups (group B)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Titanium coated cups (group C)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Uncoated cups (group A)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite and titanium coated cups (groups B and C)
Number of subjects: 185
Study: 8788220

Group type: EXPERIMENTAL
Intervention: Visual prestimulus at 0.1 s and 1 s ISI in the warned group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual prestimulus at 0.1 s ISI in the unwarned group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual prestimulus at 0.1 s ISI in the warned group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual prestimulus at all three intervals in the warned group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acoustic prestimulus at 0.1 s and 1 s ISI in the warned group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acoustic prestimulus at 0.1 s ISI in the unwarned group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual and acoustic prestimuli at 0.1 s ISI in the warned group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual and acoustic prestimuli at 0.1 s ISI in the unwarned group
Number of subjects: 20
Study: 2319784

Group type: EXPERIMENTAL
Intervention: Closed technique (group I)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Open technique (group II)
Number of subjects: 63
Study: 7437583

Group type: EXPERIMENTAL
Intervention: Broad band noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1,000 Hz pure tone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 250 Hz pure tone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-sound controls
Number of subjects: 0
Study: 31119383

Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (IA-TXA)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (IV-TXA)
Number of subjects: 228

Group type: COMPARATOR
Intervention: No-TXA
Number of subjects: 228

Group type: COMPARATOR
Intervention: Open-box TKA
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Closed-box TKA
Number of subjects: 228
Study: 27048705

Group type: EXPERIMENTAL
Intervention: Changing Talk (CHAT) communication training
Number of subjects: 42
Study: 25957542

Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (180 mg capsules once daily for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (once daily for 12 weeks)
Number of subjects: 60
Study: 23333782

Group type: EXPERIMENTAL
Intervention: Automated electronic alerts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no alerts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-intervention follow-up (after alerts ceased)
Number of subjects: 0
Study: 21392474

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 48
Study: 18486308

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17709252

Group type: EXPERIMENTAL
Intervention: Normothermic organ bath
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical verapamil-nitroglycerin solution
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of normothermic organ bath and verapamil-nitroglycerin solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no antispasmodic treatment)
Number of subjects: 80
Study: 14717629

Group type: EXPERIMENTAL
Intervention: Collective self-verification with high certainty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ties to source of self-verification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salience of collective self
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Importance of group identification
Number of subjects: 0
Study: 11678970

Group type: EXPERIMENTAL
Intervention: Uncomplicated Type 2 diabetes
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 38
Study: 9298430

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 543
Study: 8485065

Group type: EXPERIMENTAL
Intervention: xamoterol (0.2 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 3524789

Group type: EXPERIMENTAL
Intervention: Chemotherapy (6-mercaptopurine 70 mg/m2 days 1-14, methotrexate 15 mg/m2 twice weekly days 15-28, reinduction with daunorubicin 35 mg/m2 and vincristine 1 mg/m2 day 29)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus stanozolol (0.15 mg/kg/day)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 6-thioguanine (70 mg/m2 orally on 4 consecutive days) and cytosine arabinoside (80 mg/m2 subcutaneously day 5 every week)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus irradiated blast cells treated with neuraminidase
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 295

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 295
Study: 31865906

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Structured exercise
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination of MBSR and structured exercise
Number of subjects: 41
Study: 28687420

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 326

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 326
Study: 25970439

Group type: EXPERIMENTAL
Intervention: Calcium-rich dairy based meal (1352 ± 53 mg calcium)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control meal (46 ± 7 mg calcium)
Number of subjects: 32
Study: 23123039

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5% at 2 cc/h)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (0.5% saline at 2 cc/h)
Number of subjects: 67
Study: 21721397

Group type: EXPERIMENTAL
Intervention: Nurse-led, home-based pulmonary rehabilitation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 19002073

Group type: EXPERIMENTAL
Intervention: Depth Jump (DJ) training for 6 weeks, twice weekly
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ) training for 6 weeks, twice weekly
Number of subjects: 12
Study: 16481803

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 3 mg.kg‐1 (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg‐1 (group 3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine aerosol 10% to oropharyngolaryngeal structures topically (group 4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.9% saline physiologic 5 mL (group 2)
Number of subjects: 100
Study: 15061262

Group type: EXPERIMENTAL
Intervention: Planar bone scintigraphy using 99mTc methylene diphosphonate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SPECT bone scintigraphy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Planar scans
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SPECT scans
Number of subjects: 28

Group type: COMPARATOR
Intervention: X-ray results
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SPECT results
Number of subjects: 28
Study: 10869301

Group type: EXPERIMENTAL
Intervention: Phlebotomy plus interferon
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Phlebotomy alone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 96
Study: 9542000

Group type: EXPERIMENTAL
Intervention: Topinambur concentrate
Number of subjects: 0
Study: 8239044

Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 15
Study: 3519093

Group type: EXPERIMENTAL
Intervention: Antacid plus oxethazaine (8 ml doses as needed for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antacid alone (8 ml doses as needed for 4 weeks)
Number of subjects: 40
Study: 3661486

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glucose polymers
Number of subjects: 8
Study: 31759034

Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy (EUS-GE)
Number of subjects: 22
Study: 31590285

Group type: EXPERIMENTAL
Intervention: Isomaltulose (ISO) 40g/d
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sucrose (SUC) 40g/d
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Isomaltulose (ISO)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Breakfast containing Isomaltulose (ISO)
Number of subjects: 64
Study: 27522164

Group type: EXPERIMENTAL
Intervention: Docetaxel and Prednisone with Lenalidomide
Number of subjects: 208

Group type: COMPARATOR
Intervention: Docetaxel and Prednisone with Placebo
Number of subjects: 208